- Home
- CNSP vs MBRX Comparison
CNSP vs MBRX Comparison
Compare CNSP & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- MBRX
- Stock Information
- Founded
- CNSP 2017
- MBRX 2015
- Country
- CNSP United States
- MBRX United States
- Employees
- CNSP N/A
- MBRX N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- CNSP Health Care
- MBRX Health Care
- Exchange
- CNSP Nasdaq
- MBRX Nasdaq
- Market Cap
- CNSP 6.5M
- MBRX 5.1M
- IPO Year
- CNSP 2019
- MBRX 2016
- Fundamental
- Price
- CNSP $0.10
- MBRX $1.23
- Analyst Decision
- CNSP Strong Buy
- MBRX Strong Buy
- Analyst Count
- CNSP 1
- MBRX 2
- Target Price
- CNSP $0.50
- MBRX $24.00
- AVG Volume (30 Days)
- CNSP 29.2M
- MBRX 38.4K
- Earning Date
- CNSP 03-31-2025
- MBRX 03-21-2025
- Dividend Yield
- CNSP N/A
- MBRX N/A
- EPS Growth
- CNSP N/A
- MBRX N/A
- EPS
- CNSP N/A
- MBRX N/A
- Revenue
- CNSP N/A
- MBRX N/A
- Revenue This Year
- CNSP N/A
- MBRX N/A
- Revenue Next Year
- CNSP N/A
- MBRX N/A
- P/E Ratio
- CNSP N/A
- MBRX N/A
- Revenue Growth
- CNSP N/A
- MBRX N/A
- 52 Week Low
- CNSP $0.08
- MBRX $0.40
- 52 Week High
- CNSP $23.90
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- CNSP 41.60
- MBRX 31.81
- Support Level
- CNSP $0.09
- MBRX $1.33
- Resistance Level
- CNSP $0.10
- MBRX $1.82
- Average True Range (ATR)
- CNSP 0.01
- MBRX 0.13
- MACD
- CNSP -0.00
- MBRX -0.02
- Stochastic Oscillator
- CNSP 43.33
- MBRX 13.17
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.